Acesion clinches $47M in Series B raise to advance preclinical cardiac arrhythmia candidate through PhII
Acesion Pharma has bagged 45 million euros ($47 million) in an oversubscribed Series B round. The funding will support its preclinical oral potassium channel inhibitor for the prevention of atrial fibrillation (AF) recurrence through Phase II.
The Series B was co-led by new US-based backers Canaan and Alpha Wave, with support from Global BioAccess Fund and existing investor Novo Holdings.
The funds will be used to advance Copenhagen-based Acesion’s potassium channel inhibitor for the chronic maintenance treatment of AF, dubbed AP31969, into the clinic and to the end of Phase II development.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.